Loading…
Loading…
Performance hypothesis
The most energetic but honest framing is that Vilon might support performance indirectly through thymic and microvascular biology, not as a direct replacement for EPO or androgens.
Mechanism chain
A Russian type 1 diabetes abstract reports that Vilon improved antithrombin III, Protein C, and fibrinolysis markers in a DIC-like picture.
If natural anticoagulants rise and fibrinolysis improves, capillary flow and oxygen delivery could in theory improve. This is a hypothesis, not a measured outcome.
Better microvascular flow could translate to sustained effort and faster recovery. No Vilon athlete trial has measured VO2 max, lactate, or time to exhaustion.
Comparison matrix
| Feature | Vilon | EPO | Androgens |
|---|---|---|---|
| Primary mechanism | Thymus / immune / coagulation-fibrinolysis hypothesis | Red blood cell mass and oxygen carrying capacity | Androgen receptor signaling in muscle and blood |
| Athlete data | No direct Vilon performance trial recovered | Extensive; banned in sport | Extensive; banned in sport |
| Risk profile | Unknown in healthy athletes; no established dose | Polycythemia, thrombosis, cardiovascular events | Hormonal suppression, cardiovascular and hepatic risk |
| Regulatory status | Research / supplement context; not a drug | Prescription-only; banned by WADA | Prescription or banned; controlled in many jurisdictions |
Primary mechanism
Athlete data
Risk profile
Regulatory status
Precision check
The strongest Vilon coagulation signal is an abstract in type 1 diabetes reporting improvement in a DIC-like picture involving antithrombin III, Protein C, and fibrinolysis.
Microvascular flow, oxygen delivery, endurance, and recovery are a mechanistic hypothesis in healthy athletes, not measured outcomes. Do not compare Vilon as equivalent to EPO or androgens.
Athlete history
Secondary accounts tie the Khavinson peptide class, especially Pinealon, to Soviet and Russian sport. We did not recover primary documentation that names Olympic athletes using Vilon specifically.
That absence matters. Anecdotal reports of use are not controlled trials, and performance claims without primary data should not be treated as evidence.